查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
静脉血栓栓塞症治疗市场规模、份额和成长分析（按产品、适应症、最终用户和地区划分）—产业预测（2026-2033 年）
市场调查报告书
商品编码
1897181

静脉血栓栓塞症治疗市场规模、份额和成长分析（按产品、适应症、最终用户和地区划分）—产业预测（2026-2033 年）

Venous Thromboembolism Treatment Market Size, Share, and Growth Analysis, By Product, By Disease Indication, By End User, By Region - Industry Forecast 2026-2033
出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格
简介目录

全球静脉血栓栓塞症治疗市场规模预计在 2024 年达到 23.1 亿美元，从 2025 年的 24.3 亿美元增长到 2033 年的 35.8 亿美元，在预测期（2026-2033 年）内复合年增长率为 5%。

全球静脉血栓栓塞症(VTE) 治疗市场专注于解决血栓这一严重的健康问题，血栓可导致肺动脉栓塞和深层静脉栓塞症等疾病。推动市场发展的关键因素包括与久坐生活方式、人口老化和外科手术相关的 VTE 盛行率不断上升，从而催生了对有效治疗方法的需求。抗凝血治疗的创新，特别是直接口服抗凝血剂 (DOAC) 和注射剂，与传统疗法相比，在改善患者预后的同时降低了出血风险。人们对 VTE 风险因素的认识不断提高，以及对早期诊断重要性的重视，也进一步推动了市场扩张。儘管仍存在一些挑战，例如需要製定个人化的治疗策略和确保患者依从性，但该市场在提供拯救生命的治疗方面发挥的关键作用仍然凸显。

全球静脉血栓栓塞症治疗市场驱动因素

静脉血栓栓塞症症（VTE）病例的不断增加是推动全球治疗市场发展的主要因素。这一增长归因于多种因素，包括人口老化、久坐的生活方式以及术后併发症风险的增加。鑑于VTE可能带来的严重健康后果，对有效检测和治疗方案的需求日益迫切。人们对VTE及其潜在併发症的认识不断提高，预计将增加对创新治疗方法和管理方案的需求，从而进一步推动市场扩张和新治疗方法的研发。

限制全球静脉血栓栓塞症治疗市场的因素

全球静脉血栓栓塞症治疗市场面临许多挑战，主要归因于静脉血栓栓塞症治疗的复杂性。治疗方案可能复杂且耗时，导致患者难以坚持治疗。对联合疗法的依从性差会影响治疗效果，并最终降低现有治疗方案的整体疗效。随着患者努力应对治疗方案的种种要求，依从性差的风险也会增加，这成为静脉血栓栓塞症有效治疗进展的一大障碍。应对这些挑战对于提高该市场的治疗成功率至关重要。

全球静脉血栓栓塞症治疗市场趋势

全球静脉血栓栓塞症）治疗市场呈现出显着趋势，即直接口服抗凝血剂（DOAC）正逐渐成为首选治疗方案。这项转变主要得益于DOAC（如Apixaban、Rivaroxaban和艾多沙班）的便捷易用，与Warfarin等传统抗凝血剂相比，它们所需的监测也更少。此外，DOAC在预防和治疗VTE方面均展现出与传统抗凝血剂相当甚至更优的疗效，使其成为医护人员和患者的理想选择。这种不断变化的治疗偏好也推动了旨在改善患者预后和简化VTE治疗通讯协定的各项努力。

目录

介绍

  • 调查目标
  • 调查范围
  • 定义

调查方法

  • 资讯收集
  • 一手和二手资料方法
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 全球市场展望
  • 供需趋势分析
  • 细分市场机会分析

市场动态与展望

  • 市场规模
  • 市场动态
    • 驱动因素和机会
    • 限制与挑战
  • 波特分析

关键市场考察

  • 关键成功因素
  • 竞争程度
  • 关键投资机会
  • 市场生态系统
  • 市场吸引力指数（2025）
  • PESTEL 分析
  • 总体经济指标
  • 价值链分析
  • 定价分析

全球静脉血栓栓塞症治疗市场规模（按产品和复合年增长率划分）（2026-2033 年）

  • 非分段式空气压缩泵
  • 无梯度分段式空气压缩泵
  • 校准梯度分段气动压缩泵
  • 上部气动加压袖套
  • 下肢气动加压袖套
  • 永久性下腔静脉滤器
  • 可回收下腔静脉滤器
  • 栓塞清除球囊导管
  • 经皮血栓切除装置
  • 导管溶栓（CDT）装置

全球静脉血栓栓塞症治疗市场规模（按适应症和复合年增长率划分）（2026-2033 年）

  • 深层静脉栓塞症
  • 肺动脉栓塞

全球静脉血栓栓塞症治疗市场规模（以最终用户划分）及复合年增长率（2026-2033 年）

  • 医院
  • 导管检查室
  • 门诊手术中心

全球静脉血栓栓塞症治疗市场规模及复合年增长率（2026-2033）

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • GCC
    • 南非
    • 其他中东和非洲地区

竞争资讯

  • 前五大公司对比
  • 主要企业的市场定位（2025 年）
  • 主要市场参与者所采取的策略
  • 近期市场趋势
  • 公司市占率分析（2025 年）
  • 主要企业公司简介
    • 公司详情
    • 产品系列分析
    • 依业务板块进行公司股票分析
    • 2023-2025年营收年比比较

    主要企业简介

    • 强生公司（美国）
    • 辉瑞公司（美国）
    • 拜耳股份公司（德国）
    • 百时美施贵宝（美国）
    • 第一三共株式会社（日本）
    • 勃林格殷格翰（德国）
    • 诺华公司（瑞士）
    • Aspen Pharmacare Holdings Limited（南非）
    • 雅培实验室（美国）
    • 美敦力公司（爱尔兰）
    • 波士顿科学公司（美国）
    • 康德乐公司（美国）
    • 泰尔茂株式会社（日本）
    • 库克医疗（美国）
    • Getinge AB（瑞典）
    • 泰利福公司（美国）
    • 史密斯+内普（英国）
    • 百特国际有限公司（美国）
    • 仪器实验室（美国）

结论与建议

简介目录
Product Code: SQMIG35D2196

Global Venous Thromboembolism Treatment Market size was valued at USD 2.31 Billion in 2024 and is poised to grow from USD 2.43 Billion in 2025 to USD 3.58 Billion by 2033, growing at a CAGR of 5% during the forecast period (2026-2033).

The global market for venous thromboembolism (VTE) treatment focuses on addressing the serious health issue of blood clots that can lead to conditions such as pulmonary embolism and deep vein thrombosis. Key drivers of this market include the rising prevalence of VTE linked to sedentary lifestyles, aging populations, and surgical interventions, which creates a demand for effective treatments. Innovations in anticoagulant therapies, particularly direct oral anticoagulants (DOACs) and injectable options, enhance patient outcomes while reducing bleeding risks compared to traditional treatments. Growing awareness of VTE risk factors and the importance of early diagnosis further fuels market expansion. Challenges remain, including the need for personalized treatment strategies and ensuring patient adherence, underscoring the market's critical role in delivering life-saving care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Venous Thromboembolism Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Venous Thromboembolism Treatment Market Segments Analysis

Global Venous Thromboembolism Treatment Market is segmented by Product, Disease Indication, End User and region. Based on Product, the market is segmented into Non-Segmented Pneumatic Compression Pumps, Segmented Pneumatic Compression Pumps without Gradient, Segmented Pneumatic Compression Pumps with Calibrated Gradient, Upper Pneumatic Compression Sleeves, Lower Pneumatic Compression Sleeves, Permanent Inferior Vena Cava Filters, Retrievable Inferior Vena Cava Filters, Embolectomy Balloon Catheters, Percutaneous Thrombectomy Devices and Catheter-Directed Thrombolysis (CDT) Devices. Based on Disease Indication, the market is segmented into Deep Venous Thrombosis and Pulmonary Embolism. Based on End User, the market is segmented into Hospitals, Catheterisation Laboratories and Ambulatory Surgical Centres. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Venous Thromboembolism Treatment Market

The rising prevalence of Venous Thromboembolism (VTE) cases is a primary factor propelling the global treatment market. This increase can be attributed to several influences, including an aging population, sedentary lifestyles, and heightened risks associated with post-surgical conditions. Given the serious health implications associated with VTE, the need for effective detection and treatment solutions has become increasingly urgent. As awareness of VTE and its potential complications grows, the demand for innovative therapies and management options is expected to rise, further driving market expansion and the development of new treatment modalities.

Restraints in the Global Venous Thromboembolism Treatment Market

The Global Venous Thromboembolism Treatment market faces significant challenges due to the complexities associated with managing venous thromboembolism. Treatment regimens can be intricate and may extend over an extended duration, leading to difficulties in patient compliance. This lack of adherence to prescribed therapies can adversely affect treatment outcomes, ultimately hindering the overall effectiveness of the therapeutic options available. As patients grapple with the demands of their regimens, the likelihood of non-compliance increases, posing a crucial barrier that can deter progress in managing venous thromboembolism effectively. Addressing these issues is essential for improving treatment success rates in this market.

Market Trends of the Global Venous Thromboembolism Treatment Market

The Global Venous Thromboembolism (VTE) Treatment market is witnessing a significant trend towards the adoption of Direct Oral Anticoagulants (DOACs) as the preferred choice for therapy. This shift is driven by the convenience and ease of administration associated with DOACs such as apixaban, rivaroxaban, and edoxaban, which require minimal monitoring compared to traditional anticoagulants like warfarin. Furthermore, DOACs have demonstrated comparable or superior efficacy in both the prevention and treatment of VTE, making them an attractive option for healthcare providers and patients alike. This evolving preference underscores a broader commitment to enhancing patient outcomes and streamlining treatment protocols in VTE management.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2025
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Venous Thromboembolism Treatment Market Size by Product & CAGR (2026-2033)

  • Market Overview
  • Non-Segmented Pneumatic Compression Pumps
  • Segmented Pneumatic Compression Pumps without Gradient
  • Segmented Pneumatic Compression Pumps with Calibrated Gradient
  • Upper Pneumatic Compression Sleeves
  • Lower Pneumatic Compression Sleeves
  • Permanent Inferior Vena Cava Filters
  • Retrievable Inferior Vena Cava Filters
  • Embolectomy Balloon Catheters
  • Percutaneous Thrombectomy Devices
  • Catheter-Directed Thrombolysis (CDT) Devices

Global Venous Thromboembolism Treatment Market Size by Disease Indication & CAGR (2026-2033)

  • Market Overview
  • Deep Venous Thrombosis
  • Pulmonary Embolism

Global Venous Thromboembolism Treatment Market Size by End User & CAGR (2026-2033)

  • Market Overview
  • Hospitals
  • Catheterisation Laboratories
  • Ambulatory Surgical Centres

Global Venous Thromboembolism Treatment Market Size & CAGR (2026-2033)

  • North America (Product, Disease Indication, End User)
    • US
    • Canada
  • Europe (Product, Disease Indication, End User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Product, Disease Indication, End User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Product, Disease Indication, End User)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Product, Disease Indication, End User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • Johnson & Johnson (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol Myers Squibb (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Daiichi Sankyo Company, Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Boehringer Ingelheim (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aspen Pharmacare Holdings Limited (South Africa)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Abbott Laboratories (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Medtronic plc (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Boston Scientific Corporation (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cardinal Health, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Terumo Corporation (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cook Medical (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Getinge AB (Sweden)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teleflex Incorporated (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Smith+Nephew (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Baxter International Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Instrumentation Laboratory (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations